31 July 2023
31 July 2023
In the hunt for a functional cure for Hepatitis B, what treatment methods are researchers using? Are any trials close to finding one?
As per the DMC guidance, the trial will be progressed without any modifications to analyse EFS.
The trial will analyse the efficacy and safety of zigakibart versus a placebo in 272 IgAN patients.
Each week, Pharmaceutical Technology’s journalists explore movements in job postings that shed light on hiring trends in our sector.
There are no anti-sclerostin antibody therapies currently approved for usage in China.
The company intends to submit an IND application to the US FDA for NCP indication in the fourth quarter of 2023.
The additional aim of the first-in-human study is to determine the Phase II recommended dose.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
